CXCL11 is highly expressed in the immunoreactive subtype, and its ligand CXCL11 and receptor CXCR3 characterize this subtype, with the CXCL11-CXCR3 signaling pathway being a therapeutic target for ovarian cancer [55]. This evidence concerns the gene CXCL11 and ovarian carcinoma.